Malaria in the sights of BioNTech after Covid-19

The German biotechnology company BioNTech has made a name for itself in recent months with the effectiveness of its vaccine against Covid-19, which it has produced together with the American laboratory Pfizer. Based on this experience with the type of vaccine, ARN, the German company wants to fight a disease that is causing great devastation in tropical environments, malaria.

“The probability of success is high”

On Monday, July 26, 2021, the German laboratory announced its intention to use messenger RNA technology to fight malaria. To this end, he plans to start clinical trials for this product next year. The information was announced in a press release. “BioNTech intends to develop the first mRNA vaccine for the prevention of malaria,” said BioNTech. Messenger RNA technology is promising to say the least, because according to BioNTech’s director and co-founder Ugur Sahin, “the probability of success is high”. Studies on this vaccine are being carried out in Africa, but also in “other regions where malaria is common”.

A vaccine with 77% effectiveness

They also take place in Germany as part of the program supported by the Center for Disease Prevention and Control of the African Union (Africa CDC), the European Union and the World Health Organization (WHO). There is still no officially approved vaccine against malaria for the protocol. In April, however, a vaccine candidate developed by Oxford University emerged with an efficacy of 77%. This vaccine, at an unprecedented rate, could be approved by the authorities in two years.

View comments

Related Articles

Back to top button